Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction

被引:75
作者
Udelson, JE [1 ]
Konstam, MA [1 ]
机构
[1] Tufts Univ, Sch Med, Div Cardiol, Tufts New England Med Ctr, Boston, MA 02111 USA
关键词
heart failure; drug therapy; remodeling;
D O I
10.1054/jcaf.2002.129289
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: A major advance in understanding the pathophysiology of the heart failure syndrome has been an understanding of the process of left ventricular (LV) remodeling. After any insult to the left ventricle resulting in diminished systolic performance and stroke volume, a series of histopathologic changes in the myocardium and structural changes in the LV chamber occurs over time. Methods and Results: Early work on understanding this process of LV remodeling emerged from the studies of Pfeffer and colleagues, who used a rat model of myocardial infarction (MI). Compared to those with smaller MIs, rats with larger induced MIs underwent a substantially greater degree of chamber remodeling over time, and importantly, these structural changes were associated with significantly higher morality. These studies established for the first time the relation between the structural changes now widely known as LV remodeling and a natural history outcome in the setting of LV systolic dysfunction. Subsequently, these investigators demonstrated that angiotensin-converting enzyme (ACE) inhibition with captopril, when initiated soon after the induced MI, attenuated the remodeling process. Also observed was an improvement in survival among rats in whom the remodeling process has been attenuated. These important data paved the way for human studies that have subsequently provided substantial evidence to support two important concepts: (1) that LV remodeling is related to clinical outcomes that represent the natural history of the heart failure syndrome such as mortality and surrogate markers of the progression of heart failure, and (2) that therapeutic interventions in humans that slow or reverse the process of LV remodeling, such as ACE inhibitors and beta-blockers, appear to have a favorable effect on that natural history. Conclusions: This review will examine the issue of the relation between LV remodeling and clinical outcomes in the human heart failure syndrome from several interrelated aspects: (1) the relation between LV volume at one time point and subsequent oucome, (2) the relation between changes in LV volumes over time (LV remodeling) and clinical outcomes, and (3) the relation between the effect of medical therapeutic interventions on the LV remodeling process and the effect of those same medical interventions on natural history outcomes in human heart failure.
引用
收藏
页码:S465 / S471
页数:7
相关论文
共 25 条
[1]  
Antonopoulos GV, 1999, CIRCULATION, V100, P296
[2]   Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure [J].
Bozkurt, B ;
Torre-Amione, G ;
Warren, MS ;
Whitmore, J ;
Soran, OZ ;
Feldman, AM ;
Mann, DL .
CIRCULATION, 2001, 103 (08) :1044-1047
[3]   THE USE OF BIPLANE ANGIOCARDIOGRAPHY FOR THE MEASUREMENT OF LEFT VENTRICULAR VOLUME IN MAN [J].
DODGE, HT ;
SANDLER, H ;
BALLEW, DW ;
LORD, JD .
AMERICAN HEART JOURNAL, 1960, 60 (05) :762-776
[4]   Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease [J].
Doughty, RN ;
Whalley, GA ;
Gamble, G ;
MacMahon, S ;
Sharpe, N ;
Krum, H ;
Murray, Y ;
Tonkin, A ;
Trotter, A ;
Burton, R ;
Garrett, J ;
Lane, G ;
Watts, J ;
Geddes, C ;
Hall, C ;
Stephensen, J ;
Woodhouse, S ;
Davidson, T ;
Bradbury, J ;
Hamer, A ;
Hopkins, L ;
Jackson, D ;
Cross, D ;
Moreland, F ;
Hawtin, B ;
Kimber, V ;
Saunders, M ;
Thomson, A ;
Colquhoun, D ;
Goldsmith, J ;
Hicks, B ;
Bond, C ;
Flett, S ;
Murphy, J ;
Bruning, J ;
Jellyman, T ;
Nairn, L ;
Bartram, H ;
McCulloch, A ;
Milne, A ;
Prasad, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 29 (05) :1060-1066
[5]   PREDICTORS OF TOTAL MORTALITY AND SUDDEN-DEATH IN MILD TO MODERATE HEART-FAILURE [J].
GRADMAN, A ;
DEEDWANIA, P ;
CODY, R ;
MASSIE, B ;
PACKER, M ;
PITT, B ;
GOLDSTEIN, S .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1989, 14 (03) :564-570
[6]   Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure [J].
Hampton, JR ;
vanVeldhuisen, DJ ;
Kleber, FX ;
Cowley, AJ ;
Ardia, A ;
Block, P ;
Cortina, A ;
Cserhalmi, L ;
Follath, F ;
Jensen, G ;
Kayanakis, J ;
Lie, KI ;
Mancia, G ;
Skene, AM .
LANCET, 1997, 349 (9057) :971-977
[7]   EFFECTS OF THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ENALAPRIL ON THE LONG-TERM PROGRESSION OF LEFT-VENTRICULAR DILATATION IN PATIENTS WITH ASYMPTOMATIC SYSTOLIC DYSFUNCTION [J].
KONSTAM, MA ;
KRONENBERG, MW ;
ROUSSEAU, MF ;
UDELSON, JE ;
MELIN, J ;
STEWART, D ;
DOLAN, N ;
EDENS, TR ;
AHN, S ;
KINAN, D ;
HOWE, DM ;
KILCOYNE, L ;
METHERALL, J ;
BENEDICT, C ;
YUSUF, S ;
POULEUR, H .
CIRCULATION, 1993, 88 (05) :2277-2283
[8]   EFFECTS OF THE ANGIOTENSIN CONVERTING-ENZYME-INHIBITOR ENALAPRIL ON THE LONG-TERM PROGRESSION OF LEFT-VENTRICULAR DYSFUNCTION IN PATIENTS WITH HEART-FAILURE [J].
KONSTAM, MA ;
ROUSSEAU, MF ;
KRONENBERG, MW ;
UDELSON, JE ;
MELIN, J ;
STEWART, D ;
DOLAN, N ;
EDENS, TR ;
AHN, S ;
KINAN, D ;
HOWE, DM ;
KILCOYNE, L ;
METHERALL, J ;
BENEDICT, C ;
YUSUF, S ;
POULEUR, H .
CIRCULATION, 1992, 86 (02) :431-438
[9]   USE OF EQUILIBRIUM (GATED) RADIONUCLIDE VENTRICULOGRAPHY TO QUANTITATE LEFT-VENTRICULAR OUTPUT IN PATIENTS WITH AND WITHOUT LEFT-SIDED VALVULAR REGURGITATION [J].
KONSTAM, MA ;
WYNNE, J ;
HOLMAN, BL ;
BROWN, EJ ;
NEILL, JM ;
KOZLOWSKI, J .
CIRCULATION, 1981, 64 (03) :578-585
[10]   IMPACT OF LEFT-VENTRICULAR CAVITY SIZE ON SURVIVAL IN ADVANCED HEART-FAILURE [J].
LEE, TH ;
HAMILTON, MA ;
STEVENSON, LW ;
MORIGUCHI, JD ;
FONAROW, GC ;
CHILD, JS ;
LAKS, H ;
WALDEN, JA .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 72 (09) :672-676